AbbVie (NYSE: ABBV) announced today that it has completed its acquisition of Aliada Therapeutics. With the completion of the acquisition, Aliada is now a part of AbbVie.

AbbVie has completed its acquisition of Aliada Therapeutics which includes Aliada’s disease-modifying therapy for Alzheimer’s disease.

RA Capital Management, LP (RA Capital), a multi-stage investment manager dedicated to evidence-based investing in public and private healthcare, life sciences, and planetary health companies, today ...

We recently compiled a list of the 11 Best Cosmetic Surgery and Aesthetics Stocks to Invest in Now. In this article, we are ...

AbbVie has boosted its Alzheimer's disease pipeline with a $1.4 billion cash deal to buy Aliada Therapeutics and its anti-amyloid antibody ALIA-1758, which is in phase 1 testing. If consummated ...

Saskatchewan Blue Cross, a leading health and wellness solutions provider, is dedicated to making a meaningful difference in ...

It is currently in the process of acquiring Aliada Therapeutics for $1.4 billion, primarily for its Alzheimer’s treatment in pipeline. 2. How Are AbbVie’s Profit Margins Trending? Although ...

AbbVie continues to be a leader in the global ... its portfolio of product candidates due to the acquisition of Aliada Therapeutics at the end of October 2024 and Cerevel Therapeutics.

Power Lifetm by Tony Horton, the premium supplement brand designed to fuel active, healthy living, is celebrating its 5th anniversary. Since its launch in 2020, Power Life has become a game changer in ...

AbbVie also said it would pay $1.4 billion for Aliada Therapeutics and its Alzheimer’s treatment. Plus, it recently received FDA approval for its Parkinson’s treatment. With shares near an all ...

It is currently in the process of acquiring Aliada Therapeutics for $1.4 billion, primarily for its Alzheimer’s treatment in the pipeline. Looking forward, we expect both AbbVie and J&J’s ...